Newsroom

Sorted by: Latest

-

Moog Inc. Announces Offering of Senior Notes

EAST AURORA, N.Y.--(BUSINESS WIRE)--Moog Inc. Announces Offering of Senior Notes...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Growth Strength UCITS ETF 09.03.2026 FTGS.LN IE000YZLMXT9 25,002.00 USD 560,003.30 22.398  ...
-

bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies launches 2,000-patient longitudinal study for its CyPath Lung noninvasive diagnostic for lung cancer....
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Moderate Buffer UCITS ETF - February 09.03.2026 GFEB.LN IE000X8M8M80 650,002.00 USD 24,258,600.75 37.321  ...
-

 Qlaris Bio Appoints Fred Guerard, Pharm.D., as President and Chief Executive Officer

DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company developing first-in-class therapies for glaucoma, today announced the appointment of Fred Guerard, Pharm.D., as president and chief executive officer (CEO), effective March 1, 2026. He will also join the company’s Board of Directors. Dr. Guerard brings more than two decades of global leadership experience in ophthalmology and biotechnology, with a track record of advancing innovative therapies th...
-

Worthington Steel Lowers Minimum Acceptance Threshold for Kloeckner & Co Offer to 57.5%

COLUMBUS, Ohio--(BUSINESS WIRE)--Worthington Steel reduced its Kloeckner offer threshold to 57.5% and will not increase the offer price or change terms....
-

Cadre Holdings Subsidiary Is Awarded $86 Million in Contracts by General Dynamics European Land Systems

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Cadre Holdings, Inc. (NYSE: CDRE) (“Cadre” or “the Company”) announced today that its subsidiary Med-Eng, LLC has been awarded two contracts with values of $74.6 million and $11.8 million by General Dynamics European Land Systems (GDELS) to provide blast attenuation seats. Delivering best-in-class protection, the seats will be deployed in the upcoming production of Mowag EAGLE V 4x4 command and control vehicles, and the Mowag EAGLE V 6x6 medium protected amb...
-

TIAA-CREF UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Teachers Insurance and Annuity Association of America/TIAA-CREF Investment Management, LLC/Teachers Advisors, LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle compan...
-

HSBC Bank Plc UK Regulatory Announcement: FRN Variable Rate Fix

LONDON--(BUSINESS WIRE)--  09-March-2026 Issue: Severn Trent Utilities Finance Plc Series 111 XS2600998335 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 21-September-2025 Date To: 21-March-2026 Record Date: 20-March-2026 Value Date: 23-March-2026 Benchmark Rate: 2.155% Margin: % Total Rate: 2.3766418% Number of Days: 181 Day Count: Actual / Actual (ICMA) Interest Frequency: Semi-Annually Total Amount D...
-

Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has triggered the first $20 million contingent payment under its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The payment was triggered by contracted work orders for critical chemistry, manufacturing and controls (CMC) and production activities related to botensilimab (BOT) and balstilimab (BAL). These activities will allow Zydus to perform...